• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hematology: The case against rituximab maintenance.

作者信息

Cheson Bruce D

出版信息

Nat Rev Clin Oncol. 2009 Nov;6(11):622-4. doi: 10.1038/nrclinonc.2009.161.

DOI:10.1038/nrclinonc.2009.161
PMID:19861992
Abstract
摘要

相似文献

1
Hematology: The case against rituximab maintenance.血液学：反对利妥昔单抗维持治疗的案例。
Nat Rev Clin Oncol. 2009 Nov;6(11):622-4. doi: 10.1038/nrclinonc.2009.161.
2
Hematology: Follicular lymphoma: maintenance therapy is (often) indicated.血液学：滤泡性淋巴瘤：（通常）需要进行维持治疗。
Nat Rev Clin Oncol. 2009 Nov;6(11):624-6. doi: 10.1038/nrclinonc.2009.159.
3
[A case of follicular lymphoma of the duodenum treated with the combined therapy of anti-CD20 antibody and chemotherapy].1例采用抗CD20抗体与化疗联合治疗的十二指肠滤泡性淋巴瘤
Nihon Shokakibyo Gakkai Zasshi. 2006 Mar;103(3):301-9.
4
Use of rituximab in patients with follicular lymphoma.
Clin Oncol (R Coll Radiol). 2007 Feb;19(1):38-49. doi: 10.1016/j.clon.2006.11.009.
5
[Antibody therapy in hematology and oncology - part 1].[血液学和肿瘤学中的抗体疗法 - 第一部分]
Med Klin (Munich). 2008 Dec 15;103(12):843-59. doi: 10.1007/s00063-008-1133-9.
6
Comparative effectiveness of treatments for newly diagnosed follicular non-Hodgkin lymphoma.
Leuk Lymphoma. 2015;56(9):2728-30. doi: 10.3109/10428194.2015.1006219. Epub 2015 Mar 11.
7
Meningeal relapse by follicular lymphoma as a single mass.
Clin Transl Oncol. 2008 Mar;10(3):180-1. doi: 10.1007/s12094-008-0177-x.
8
Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.利妥昔单抗联合CHOP方案治疗乙肝病毒携带的淋巴瘤患者：一项诊断与治疗挑战
Leukemia. 2002 Sep;16(9):1884-6. doi: 10.1038/sj.leu.2402567.
9
Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma.利妥昔单抗联合多药化疗治疗小儿滤泡性淋巴瘤。
Pediatr Blood Cancer. 2011 Aug;57(2):317-20. doi: 10.1002/pbc.23110. Epub 2011 Apr 1.
10
Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.利妥昔单抗维持治疗可改善滤泡性淋巴瘤患者的总生存期——个体患者数据荟萃分析
Eur J Cancer. 2017 May;76:216-225. doi: 10.1016/j.ejca.2017.01.021. Epub 2017 Mar 21.

引用本文的文献

1
Rituximab maintenance for follicular lymphoma.利妥昔单抗维持治疗滤泡性淋巴瘤。
Nat Rev Clin Oncol. 2010 Mar;7(3):1; author reply 1. doi: 10.1038/nrclinonc.2009.161-c1.

本文引用的文献

1
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study.利妥昔单抗维持治疗复发/难治性滤泡性非霍奇金淋巴瘤：EORTC 20981 期随机分组研究的长期结果。
J Clin Oncol. 2010 Jun 10;28(17):2853-8. doi: 10.1200/JCO.2009.26.5827. Epub 2010 May 3.
2
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.在环磷酰胺、长春新碱和泼尼松治疗后使用利妥昔单抗维持治疗可延长晚期惰性淋巴瘤的无进展生存期：III期随机ECOG1496研究结果
J Clin Oncol. 2009 Apr 1;27(10):1607-14. doi: 10.1200/JCO.2008.17.1561. Epub 2009 Mar 2.
3
Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.利妥昔单抗维持治疗滤泡性淋巴瘤患者：随机试验的系统评价和荟萃分析
J Natl Cancer Inst. 2009 Feb 18;101(4):248-55. doi: 10.1093/jnci/djn478. Epub 2009 Feb 10.
4
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.钇-90 替伊莫单抗巩固治疗与晚期滤泡性淋巴瘤首次缓解后不进行额外治疗对比的 III 期试验。
J Clin Oncol. 2008 Nov 10;26(32):5156-64. doi: 10.1200/JCO.2008.17.2015. Epub 2008 Oct 14.
5
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).对于复发和难治性滤泡性及套细胞淋巴瘤患者，在使用利妥昔单抗、氟达拉滨、环磷酰胺和米托蒽醌联合方案（R-FCM）进行挽救治疗后，采用利妥昔单抗维持治疗可显著延长缓解持续时间：德国低度淋巴瘤研究组（GLSG）一项前瞻性随机研究的结果。
Blood. 2006 Dec 15;108(13):4003-8. doi: 10.1182/blood-2006-04-016725. Epub 2006 Aug 31.
6
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.利妥昔单抗维持治疗可改善复发/难治性滤泡性非霍奇金淋巴瘤患者的临床结局，无论诱导治疗期间是否使用过利妥昔单抗：一项前瞻性随机3期组间试验的结果
Blood. 2006 Nov 15;108(10):3295-301. doi: 10.1182/blood-2006-05-021113. Epub 2006 Jul 27.
7
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.利妥昔单抗联合CHOP方案与单纯CHOP方案或CHOP方案联合利妥昔单抗维持治疗老年弥漫性大B细胞淋巴瘤的比较。
J Clin Oncol. 2006 Jul 1;24(19):3121-7. doi: 10.1200/JCO.2005.05.1003. Epub 2006 Jun 5.
8
Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.最大化利妥昔单抗的治疗益处：惰性非霍奇金淋巴瘤患者的维持治疗与病情进展时再治疗——米妮·珀尔癌症研究网络的一项随机II期试验
J Clin Oncol. 2005 Feb 20;23(6):1088-95. doi: 10.1200/JCO.2005.12.191. Epub 2005 Jan 18.
9
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.与标准的每周一次共4次的治疗方案相比，利妥昔单抗对滤泡性淋巴瘤患者进行延长治疗可显著提高无事件生存期和缓解持续时间。
Blood. 2004 Jun 15;103(12):4416-23. doi: 10.1182/blood-2003-10-3411. Epub 2004 Feb 19.
10
Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.单药利妥昔单抗作为慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者的一线及维持治疗：米妮·珀尔癌症研究网络的一项II期试验
J Clin Oncol. 2003 May 1;21(9):1746-51. doi: 10.1200/JCO.2003.09.027.